Background: Anemia is common in patients with severe chronic liver disease, but its role in HBV-related decompensated cirrhosis (DeCi) is still unclear. We therefore aimed to assess the impact of anemia on prognosis in HBV-DeCi patients.
Methods: One hundred thirty-three patients diagnosed with HBV-DeCi were retrospectively collected.
Results: A total of 113 (85.0%) patients suffered from anemia in our cohort. The low hemoglobin (Hb) level group exhibited a significantly increased 28-day mortality rate compared with the high Hb group. Hb level was a predictor of 28-day mortality in HBV-DeCi patients.
Conclusions: Reduced Hb levels were associated with unfavorable prognosis in HBV-DeCi patients, and more attention should be paid to anemia in routine clinical assessments of liver cirrhosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2020.200701 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Imbalance of Homeostasis in Neutrophil Extracellular Traps is Associated with Portal Vein Thrombosis in Patients with Decompensated Cirrhosis.
J Clin Transl Hepatol
December 2024
Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Background And Aims: Portal vein thrombosis (PVT) is a challenging complication in liver cirrhosis, with no currently available sensitive diagnostic markers. This study aimed to investigate the potential of neutrophil extracellular traps (NETs) and Deoxyribonuclease (DNase) as diagnostic indicators for PVT in chronic hepatitis B (CHB)-related decompensated cirrhosis.
Methods: We analyzed 145 CHB-related decompensated cirrhosis patients from the Ditan study and 33 from the Changgung validation study, categorizing them based on PVT occurrence.
Sarcopenia is associated with new-onset acute biliary infection within 1 year in patients with hepatitis B virus-related decompensated cirrhosis.
Eur J Gastroenterol Hepatol
January 2025
Department of Gastroenterology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu Province, China.
Backgrounds: Malnutrition and sarcopenia are prevalent complications in cirrhosis. The relationship between sarcopenia and biliary infection in cirrhotic patients is not well understood. Our study aims to clarify this association.
View Article and Find Full Text PDFEfficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First-Time HBV-Related Decompensated Cirrhosis.
J Viral Hepat
October 2024
Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Clinical studies of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) treatment in patients with HBV-related decompensated cirrhosis (HBV-DC) are limited. This study evaluated the efficacy and safety of TMF versus TAF in naive-treated patients with first-time HBV-DC. Based on the antiviral drug used, patients were categorised into the TMF group and the TAF group.
View Article and Find Full Text PDFHepatic and extrahepatic metabolic modulation in hbv-related decompensated cirrhosis and acute-on-chronic liver failure.
Virulence
December 2024
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Article Synopsis
- Acute-on-chronic liver failure (ACLF) and decompensated cirrhosis (DC) are severe complications of chronic hepatitis B virus (HBV) infection, marked by metabolic disturbances in the liver and beyond.
- A study analyzed serum samples and liver tissues from patients with HBV-ACLF, HBV-DC, and control groups to explore metabolic changes, highlighting impairments in energy, amino acid, and pyrimidine metabolism specific to ACLF/DC.
- The research found that both conditions share similar abnormal serum metabolite profiles linked to inflammation and metabolic dysfunction, with unique markers for each, suggesting a connection between liver pathology and systemic inflammatory response.
Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia.
Lancet Reg Health West Pac
October 2024
The Kirby Institute, UNSW Sydney, Australia.
Article Synopsis
- A study in NSW, Australia analyzed hepatitis B (HBV) and C (HCV) notifications from 1995 to 2022, linking them to hospital and mortality records to assess liver disease outcomes.
- Results showed significant reductions in decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality, especially during the viral hepatitis elimination era (2015-2022) for HCV.
- The findings suggest that, while HBV-related improvements started earlier, HCV-related declines were more pronounced during the elimination era, indicating targets for reducing liver-related mortality were largely met by 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!